Trials make headlines. Settlements make markets. And behind a growing share of both sits a pool of capital that barely existed twenty years ago.
In 2009, Burford Capital listed on London's AIM market and raised $130 million to fund lawsuits — an idea the financial press treated as a curiosity. Seventeen years later, industry estimates put committed capital in global third-party litigation finance at roughly $15 to $18 billion. The curiosity became an asset class. The question now is not whether litigation finance is real. It is who controls it, how the money is structured, and what happens next.
A $15B+ market built on portfolio finance
The headline number needs unpacking. "Committed capital" is not deployed capital — it includes undrawn commitments in closed-end funds, and estimates vary by source. What matters more than the exact figure is the composition, because the market's center of gravity has moved decisively.
A decade ago, litigation finance meant single-case funding: a funder bankrolls one lawsuit in exchange for a slice of the recovery, typically 20–40% or a multiple of invested capital. Single-case deals still exist, but the industry's growth engine is portfolio financing — funding a law firm's or a corporate's entire book of contingent matters under one facility. Portfolios diversify case risk, compress the cost of capital for the borrower, and let funders deploy nine-figure checks instead of hunting individual claims. By 2025, the largest transactions in the market were portfolio facilities in the $100–300 million range, extended to Am Law 50 firms and Fortune 500 legal departments.
The second structural shift is monetization: companies with a large judgment or award on appeal can borrow against it, or sell a participation, turning a litigation asset into working capital today. For CFOs, that converts legal spend from a sunk cost into a balance-sheet event. Funders love it because the merits have already been adjudicated — the risk is duration and collectability, not liability.
Here is the line that explains the whole market: litigation finance turned the courthouse into an asset class. Once a claim could be underwritten like a bond — priced, tranched, diversified — institutional capital had no choice but to show up.
The major funders and how they compete
The market remains top-heavy. Burford Capital, listed in London and New York, is the largest by a clear margin, with several billion dollars in capital deployed or committed across its funds and balance sheet — its annual reports are the closest thing the industry has to a public benchmark. Omni Bridgeway, formed from the merger of Australia's IMF Bentham and Europe's Omni, is the other genuinely global platform, with particular strength in Australia, Europe, and international arbitration.
Below the giants sits a deep bench: Harbour (UK), Therium (UK), Deminor (continental Europe), Longford Capital and Parabellum in the U.S., plus a long tail of specialty funders in mass torts, patent assertion, and insolvency claims. And behind many of them: institutional money. Sovereign wealth funds, university endowments, and private credit managers have entered as limited partners or through fundless sponsors, attracted by returns that are uncorrelated with equities and credit cycles — litigation outcomes do not track the S&P 500.
Competition has compressed pricing at the top end. Where early funders routinely demanded 3x multiples of invested capital, a strong corporate portfolio facility in 2025–2026 can price closer to low-teens IRRs with downside protection — still rich versus investment-grade credit, but a sign of a maturing market. At the small end, single-case consumer and small-commercial funding remains expensive, with effective returns that still shock newcomers.
Where the market is heading
Three vectors will define the next five years. First, regulation and disclosure. U.S. federal courts remain split on whether litigation funding arrangements must be disclosed; the 2024 amendments debate, state-level disclosure statutes, and the ongoing fight over funder involvement in mass torts all point toward more sunlight, not less. Funders that have built compliance infrastructure will have an edge over those that treated disclosure as optional.
Second, the corporate legal department as customer. The fastest-growing segment is not law firms — it is in-house teams using funding to pursue affirmative recoveries (antitrust, trade secrets, contract claims) without asking the board for a litigation budget. The line every funder now repeats in pitch meetings: the best-funded plaintiff in America is a general counsel spending someone else's money.
Third, secondary markets. As portfolios season, expect more trading of litigation-finance positions between funders — securitization-style structures already exist in embryonic form. A real secondary market would do for litigation finance what it did for private equity: bring in a new class of buyers, standardize valuation, and push the asset class fully into the institutional mainstream.
The $15–18 billion figure will look small in retrospect if even two of those three vectors play out. Litigation has always been expensive. Finance just made it legible.
Understanding what litigation costs — and who is willing to pay for it — starts with real numbers. LawsuitCosts.com tracks the economics of disputes, from funder pricing to per-phase litigation budgets.